Hengrui Pharmaceutical (600276.SH): SHR-9803 clinical trial approved for injection

Zhitongcaijing · 03/26 08:49

Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) announced that the company received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for SHR-9803 for injection, and the State Drug Administration agreed to conduct clinical trials of this single drug in patients with advanced solid tumors.